BridgeBio Pharma Inc (NASDAQ: BBIO) is 31.09% higher on its value in year-to-date trading and has touched a low of $21.62 and a high of $41.04 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BBIO stock was last observed hovering at around $36.46 in the last trading session, with the day’s loss setting it -0.49%.
Currently trading at $35.97, the stock is 8.40% and 22.95% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.15 million and changing -1.34% at the moment leaves the stock 32.99% off its SMA200. BBIO registered -4.94% loss for a year compared to 6-month gain of 38.67%. The firm has a 50-day simple moving average (SMA 50) of $29.0185 and a 200-day simple moving average (SMA200) of $27.001175.
The stock witnessed a 28.51% loss in the last 1 month and extending the period to 3 months gives it a 47.18%, and is -3.02% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.56% over the week and 4.93% over the month.
BridgeBio Pharma Inc (BBIO) has around 550 employees, a market worth around $6.80B and $217.76M in sales. Profit margin for the company is -201.53%. Distance from 52-week low is 66.37% and -12.35% from its 52-week high. The company has generated returns on investments over the last 12 months (-88.62%).
with sales reaching $4.01M over the same period.The EPS is expected to grow by 36.14% this year, but quarterly earnings will post 2,940.00% year-over-year. Quarterly sales are estimated to grow 129.81% in year-over-year returns.
348.0 institutions hold shares in BridgeBio Pharma Inc (BBIO), with institutional investors hold 96.89% of the company’s shares. The shares outstanding are 188.99M, and float is at 147.77M with Short Float at 13.79%. Institutions hold 94.07% of the Float.
The top institutional shareholder in the company is KOHLBERG KRAVIS ROBERTS & CO. L.P. with over 31.06 million shares valued at $786.77 million. The investor’s holdings represent 16.5582 of the BBIO Shares outstanding. As of 2024-06-30, the second largest holder is VIKING GLOBAL INVESTORS LP with 25.12 million shares valued at $636.31 million to account for 13.3917 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 14.05 million shares representing 7.4924 and valued at over $356.01 million, while BLACKROCK INC. holds 6.636 of the shares totaling 12.45 million with a market value of $315.31 million.
BridgeBio Pharma Inc (BBIO) Insider Activity
The most recent transaction is an insider sale by STEPHENSON BRIAN C, the company’s Secretary, Treasurer & CFO. SEC filings show that STEPHENSON BRIAN C sold 68,000 shares of the company’s common stock on Jan 28 ’25 at a price of $36.29 per share for a total of $2.47 million. Following the sale, the insider now owns 93758.0 shares.
BridgeBio Pharma Inc disclosed in a document filed with the SEC on Jan 28 ’25 that Kumar Neil (Chief Executive Officer) sold a total of 326,932 shares of the company’s common stock. The trade occurred on Jan 28 ’25 and was made at $36.29 per share for $11.86 million. Following the transaction, the insider now directly holds 5.37 million shares of the BBIO stock.
Still, SEC filings show that on Jan 29 ’25, Kumar Neil (Chief Executive Officer) disposed off 273,068 shares at an average price of $36.35 for $9.93 million. The insider now directly holds 5,098,447 shares of BridgeBio Pharma Inc (BBIO).
